- Coordinator
- Klinikum Der Universitaet Regensburg, Germany
- Runs
- 1 September 2023 to 31 August 2027
- Status
- Running
- EU funding
- €2.6m
- Total cost
- —
- Partners
- 25 organisations in 7 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101119855
What the project is doing
In the project's own words, from its summary on CORDIS.
Organ transplantation remains the only definitive treatment for end-stage heart, lung, liver or kidney disease. Early transplant outcomes are now generally excellent, dramatically reducing patients’ mortality and morbidity. Nevertheless, transplantation still faces significant obstacles, especially long-term immunosuppression-related toxicity and chronic decline of transplant function, which are the leading causes of transplant failure.
To break these barriers, which represent a very significant societal and economic burden in the EU, there is a need for innovative therapies to lessen our reliance on conventional immunosuppression and better control non-resolving inflammation. Extracorporeal photopheresis (ECP) is now being investigated as a personalized, adjunct immunosuppressive therapy in some organ transplant settings. However, ECP is regarded as a controversial therapy, primarily because current understanding of its pharmacological actions is incomplete, but also because there remain questions about optimal manufacturing processes, quality-control and personalized clinical indications.
The exTra project asks whether a better mechanistic understanding of ECP can guide us more efficiently towards novel applications. Specifically, exTra brings together European experts in clinical transplantation, immunology, pharmaceutical development, computational biology and medical device manufacture to address key questions through a coordinated, interdisciplinary effort. exTra proposes 10 independent doctoral research projects with the ambition of providing its trainees with a comprehensive understanding of basic and translational immunology, especially relating development and licensing of new immunotherapies.
Through its research and training activities, the exTra project will contribute to scientific advancement and innovation in Europe, ultimately leading to societal and economic benefits stemming from clinical innovations in transplant immunotherapy and beyond.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Klinikum Der Universitaet Regensburg | Regensburg | Germany | Coordinator |
| Medizinische Universitaet Wien | Wien | Austria | Participant |
| Albert-Ludwigs-Universitaet Freiburg | Freiburg | Germany | Associatedpartner |
| Amedes Medizinische Dienstleistungen GmbH | Gottingen | Germany | Associatedpartner |
| Friedrich-Alexander-Universitaet Erlangen-Nuernberg | Erlangen | Germany | Associatedpartner |
| Limbach Medizinisches Labor Rosenheim MVZ GbR | Rosenheim | Germany | Associatedpartner |
| Universitaet Regensburg | Regensburg | Germany | Associatedpartner |
| Universitaetsklinikum Freiburg | Freiburg | Germany | Participant |
| Universitatsklinikum Erlangen | Erlangen | Germany | Participant |
| Aniling | Badalona | Spain | Associatedpartner |
| Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer | Barcelona | Spain | Participant |
| Fundacion Instituto De Investigacion Marques De Valdecilla | Santander | Spain | Associatedpartner |
| Institut De Investigacio En Ciencies De La Salut Germans Trias I Pujol | Badalona Barcelona | Spain | Participant |
| Instituto De Salud Carlos Iii | Madrid | Spain | Participant |
| Universitat Autonoma De Barcelona | Cerdanyola Del Valles | Spain | Associatedpartner |
| Universitat De Barcelona | Barcelona | Spain | Associatedpartner |
| Immunotech SAS | Marseille | France | Associatedpartner |
| Institut Gustave Roussy | Villejuif | France | Associatedpartner |
| Innovation Acta SRL | Siena | Italy | Associatedpartner |
| Stichting Sanquin Bloedvoorziening | Amsterdam | Netherlands | Participant |
| Universiteit Van Amsterdam | Amsterdam | Netherlands | Associatedpartner |
| King's College London | London | United Kingdom | Associatedpartner |
| Quell Therapeutics Limited | London | United Kingdom | Associatedpartner |
| Therakos UK Ltd | Staines Upon Thames | United Kingdom | Associatedpartner |
| University of Newcastle Upon Tyne | Newcastle Upon Tyne | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI